EDITOR’S NOTE: At the beginning of April, #HealthCaribbean featured Cuba in our edition 2021-04-08. This newsletter does the same, with a major emphasis is on their biotechnology and biopharmaceutical sectors. Because of the U.S. embargo, Cuba has had to develop its own self-sustaining healthcare industry. Additional information can be found on our Twitter feed.
Our headline, taken from TeleSUR English edition, reads: “Cuba and Germany Will Discuss Biopharmaceutical Cooperation”. The ProCuba Center had advised that Cuba and Germany were to have participated in a virtual business forum on April 14, aimed at exploring possible cooperation in the fields of biotechnology and biopharmaceuticals.
Five years ago, BioCubafarma signed their first deal to bring Cuban pharmaceuticals to Russia. In 2019, they opened an office in Russia, and now expect to sign further deals for their products. Cuba’s Ambassador to Japan also hosted an online conference in which Japanese participants were updated on Cuba’s five vaccine candidates against COVID-19.
Cuba has started immunizing persons 19 years and over in its capital, Havana, with its Abdala Vaccine. And finally, the Doctor Carlos Miyares Cao Placental Histotherapy Center (Hisplacen) — which was founded 35 years ago — and is now considered to be a leading international institution on medicines, cosmetics and nutrients derived from the human placenta.